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Abstract
Background: Cancer is a lethal disease that results from a multifactorial process.
Progression into carcinogenesis and an abnormal cell proliferation can occur due
to the micro and macro environment as well as genetic mutations and modifications.
In this review, cancer and the microbiota – mainly bacteria that inhabit the tumour
tissue – have been discussed. The positive and negative impacts of the commensal
bacteria on tumours being protective or carcinogenic agents, respectively, and their
strategies have also been described.
Methods: Related published articles written in English language were searched from
Google Scholar, PubMed, Mendeley suggestions, as well as Google search using a
combination of the keywords ‘Microbiota, commensal bacteria, cancer, tumor’. Relevant
literature published between the years 1979 and 2018 were included in this review.
Results: The complicated nature of cancer as well as the role that might be played by
the commensal bacteria in affected tissues have been the focus of the recent studies.
The symbiotic relationships between the microbiota and the host have been shown to
confer benefits to the last. By contrast, the microbiota has been suggested to upgrade
cancer by modifying the balance of host cell proliferation and death, by provoking
chronic inflammation, and by eliciting uncontrolled innate and adaptive immunity. In
this context, aerobic and anaerobic bacteria have been isolated from various tumor
samples.
Conclusions: It can be concluded that commensal microbiota plays an important role in
the prevention of diseases including cancer. Inversely, microbiota alterations (dysbiosis)
have been found to interrupt that symbiotic correlation between the host and the
inhabitant microbiota probably leading to cancer.
Recommendations: The correlation between the commensal microbiome, antibiotics
uptake and cancer occurrence need to be investigated exclusively. Moreover,
increased attention must be paid to evaluating the effects of these microorganisms on
the currently used anticancer agents, and the role that might be played by commensal
bacteria on tumor progression or tumor regression.
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1. Introduction
Cancer is the second leading cause of death in both developed and developing coun-
tries. A normal cell must undergo many molecular changes to be transformed into a
cancer cell. Hence, the probability that such events occur in an individual cell is rising
with age [1]. Malignant transformation of cells has been attributed to many factors,
including genetic, life style, hormones, proteases, cytokines along with immune and
stromal cells [2, 3]. Recently, increased incidence of cancer cases has been reported
across the world countries including Iraq.
Cancer has been treated by numerous traditional therapeutic approaches, such as
chemotherapy and radiotherapy, which are available for around 50% of the cancer
victims [4]. Despite intensive research, no appropriate therapy for most of cancer types
has been developed [5]. However, certain microorganisms have been shown to have
the capability to control the cancer cell growth throughout the affected area [6]. The
microorganisms that live symbiotically in the bodies of human beings have been pro-
gressively documented as vital players in health and disease [7]. The tumor-associated
microbiota could play dual roles on cancer therapy. The positive effect of bacteria as
anti-tumor agents includes the important functions of their toxins, enzymes, and spores
against cancer development. While their negative influence on cancer might be via the
interference with cancer drugs preventing them from affecting cancer, adding to the
impact of dysbiosis (microbial perturbation) on enhancing carcinogenesis [8].
Many studies have focused on the use of certain bacteria as anti-cancers, such as the
findings of [9–11]. Many bacteria are activelymobile andmove away from the vasculature,
penetrate deeply, and accumulate in tumor tissue. This makes therapy based on bacteria
to achieve sufficient tissue penetration, which cannot be accomplished with other
treatments, including radiation and chemotherapy [12]. Although possible biosafety and
other harmful impacts, for example, underlying bacterial toxicity, decreased targeting
efficiency, genomic instability, and complex interactions with other treatments are the
main limitations of using bacteria to target tumors [8, 13, 14]. Altogether, because of the
important positive and negative roles that might be played by commensal bacteria in
tumor tissues, and because no more studies are available concerning the correlations
of microbiota with cancer. Therefore, this subject has been taken into account to review
the microbiome-inhabiting tumours, focusing on the existing bacteria and shedding light
on the effects and strategies of commensal bacteria on tumours as protective against
or enhancer for carcinogenesis.
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2. Methods
Related published articles written in English language were searched from Google
Scholar, PubMed, Mendeley suggestions, as well as Google search using a combination
of the keywords: ‘microbiota, commensal bacteria, cancer, tumour’. Relevant literature
published between the years 1979 and 2018 were included in this review.
3. Results
This review article included 126 references published in prestigious scientific journals.
Most of the searched literature has been published recently, with some articles being
published in the last three or four decades. The results of the search are shown in the
below sections:
3.1. Tumorigenesis
Tumorigenesis is the process that originates as cells are liberated from growth controls,
and the promotion takes place as the immune system is eluded, which in turnwill support
more mutations and increased loss of cell regulation [15]. Although genetic mutations
and alterations are essential for cancer cells proliferation [16], tumour progression and
ultimate invasion of the host also depends on the response of the host to inflammation
and antitumor immunity [17].
Importantly, angiogenesis, which is the process of formation of new blood vessels,
results when the tumor continues to multiply and becomes in need to a greater blood
supply. If the tumor breaks down, succeeding invasion to the surrounding tissues occurs.
Metastasis is the poorest outcome that takes place when cells separate from the tumour
and seed tumours at far sites [15].
3.2. Commensal bacteria
Different habitats of human body, such as the gut, skin, mucosa, vagina, mouth, nose,
conjunctiva, pharynx and urethra, among others are colonized by a large number of
microorganisms, which are called normal microflora or the microbiota [18]. In the human
body, the number of microbial cells is 10 times bigger than the number of eukaryotic
cells [7]. The microbiota of each organ is different, and there is a significant and
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functionally relevant inter-individual inconsistency of microbiota, which makes them
a possible determinant of diseases including cancer [19].
The words microbiota and microbiome are frequently used as synonyms, never-
theless, they express two different meanings: while microbiota signifies the whole
microbes (bacteria, viruses, fungi, archaea, and protozoa) in a certain environment, the
microbiome is the total genomes of a microbiota and is frequently used to express the
entity of microbial traits (functions) encoded by amicrobiota [20]. Among the commensal
microorganisms, bacteria represent the main microbiota, which predominantly colonize
skin, specially skin folds, the upper airways, mainly the nasopharynx, and somemucosal
surfaces of the genital tract, although the largest numbers of bacterial cells are present in
the digestive tract. Furthermore, the oral cavity, including tongue, teeth, and periodontal
tissues hold increased numbers of bacteria [18, 21].
Similar to normal epithelial and mucosal surfaces of the body, tumour is also occupied
by microbiome especially bacteria [22]. Interestingly, bacteria were found in 69% of var-
ious necrotic tumour specimens, which involved abdominal, pelvic, lungs, mediastinal,
lymphatic, breast, head, and neck tumours. Importantly, aerobic or facultative anaerobic
bacteria were isolated from 19% of specimens, anaerobes from 16%, and 65% of spec-
imens showed mixed aerobic and anaerobic bacteria. The predominant aerobic and
facultative anaerobic bacteria most commonly isolated were Staphylococcus aureus,
S. epidermidis, 𝜕-hemolytic streptococci, Escherichia coli, Klebsiella pneumoniae, and
Pseudomonas aeruginosa. While the anaerobic bacteria included Bacteroides spp.,
anaerobic cocci, and Propionibacterium [23].
One of the organs extensively studied for the presence of microbiota is human
breast tissue, where a varied community of bacteria were isolated, unlike what was
thought that body sites are sterile. Proteobacteria were the principal phylum isolated
[24], while Bacillus, Acinetobacter, Enterobacteriaceae, Pseudomonas, Staphylococ-
cus, Propionibacterium, Comammonadaceae, Gammaproteobacteria, and Prevotella
were the abundant taxa found in the breast tissue of the Canadian women. Enterobac-
teriaceae, Staphylococcus, Listeria welshimeri, Propionibacterium, and Pseudomonas
were mainly grown from Irish samples [24]. It has been shown that the microbiome is
different in normal, benign, and malignant breast tissue, and malignancy was associated
with an enrichment in low abundant taxa, exemplified by the genera Lactobacillus,
Fusobacterium, Atopobium, Gluconacetobacter, and Hydrogenophaga [25]. Recently,
various Gram-positive and Gram-negative bacterial species have been grown aerobi-
cally from 100 benign andmalignant breast tumour specimens of Iraqi patients. Themost
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common isolates were S. epidermidis (50.6%), although S. aureus, Bacillus species, P.
fluorescence, and Enterobacteriaceae were also isolated [26].
3.3. Effects of commensal bacteria on tumours
3.3.1. The protective role of commensal bacteria against
diseases including cancer
Symbiotic relationships are found between the host and microbiota; such relationship
grants benefits to the host [27]. The physiological interaction that occurs between
the gut microbiota, for example, and the host immune system has been shown to be
necessary in many aspects. Firstly, to avoid tissue-damaging inflammatory responses
directed against the commensal bacteria, including different species of Bacteroides
and Clostridia in the colon and Proteobacteria and Lactobacilli in the small intes-
tine. Secondly, in preventing the infection of pathogens, for example, Salmonella and
Shigella spp. Thirdly, inhibiting the uncontrolled growth of indigenous organisms such
as vancomycin-resistant enterococci andClostridium difficile [28, 29]. And finally, the gut
microbiota itself is required for an efficient mucosal repair following epithelial damage
[30].
The full development of the host’s immune system requires exposure to the micro-
biota after birth. This microbial exposure in early life has been suggested to have long-
lasting effects into later life [31]. Experimentally, delayed microbial colonization of germ-
free mice was shown to result in increased morbidity of inflammatory bowel diseases
and allergic asthma [32]. Mutually, the composition and stability of the commensal
microbiota depends on the local defence mechanisms of the host [33].
The oral cavity holds a large number of microorganisms that frequently form biofilms
[34]. The oral microflora plays a big role in responding to the infection and modulating
local immunity [35, 36]. In the nasal cavity, the normal resident S. spp. can provide
defence against pathogens. It has been observed that nasal colonization by S. aureus
could be inhibited by the nasal microflora, exemplified by S. epidermidis strain that pro-
duces a serine protease or S. lugdunensis strain that produces a thiazolidine-containing
cyclic peptide [37, 38]. Commensal bacteria colonizing the breast tissue could sustain
its health by stimulating the inflammatory responses of the host. In particular, the
abundance of the bacterium Sphingomonas yanoikuyae in breast tissue was associated
with the healthy status of women compared to the tumorous breast tissue where
spectacular decrease in the numbers of the aforementioned bacterium occurred [39].
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A typical and abundant commensal microbiota has been shown to colonize the lungs
and the vaginal mucosa, and contributes to the local immune homeostasis [40].
Skin, which is the largest organ of the body, harbours a large number of microbiota.
Germ-free mice have been shown to be more vulnerable to skin infections than mice
maintained under specific pathogen-free conditions [41]. The microbiota acts as a func-
tional luminal barrier; inhibits the growth of pathogens by competing for resources, and
maintains epithelial cell turnover via stimulating mucin production [7]. The microbiota
inhabiting epithelial barrier surfaces, including the skin and the gastrointestinal tract,
interacts with its host either directly or by means of releasing products, for example,
proteins, carbohydrates, lipids, and nucleic acid. All of these products regulate local
inflammation and immunity [42].
There are several mechanisms bywhich the commensal microbiota controls the host’s
immune response at different barrier surfaces. Staphylococcus epidermidis, for instance,
one of the commensals of skin, has been shown to assist the immune function of the skin
by reducing inflammation after injury [43], improving cutaneous T cells development, as
well as stimulating the expression of host anti-microbial peptides (AMPs) such as cathe-
licidins and β-defensins [44–47]. Specific strains of coagulase-negative staphylococcal
(CNS) spp. have been demonstrated to protect host against infectious pathogens by
producing proteins that work together with endogenous host AMPs [48, 49]. Clinical
studies have observed that strains of S. epidermidis, S. hominis, and other CNS that
produce various AMPs were insufficient in patients of atopic dermatitis colonized with
S. aureus [49]. Phenol-soluble modulins (PSMγ and PSMδ) produced by S. epidermidis
have been found to selectively kill the pathogenic bacteria, for example, S. aureus and
Streptococcus, group A [50]. Importantly, S. epidermidis of the skin has been shown to
play a protective role against skin cancer. The molecule 6-N-hydroxyaminopurine (6-
HAP) produced by S. epidermidis has been verified by [23, 51] to impair tumour growth
by inhibiting DNA polymerase activity.
In the gut, short-chain fatty acids (SCFAs), which are bacterial fermentation products
resulting from the fermentation of dietary fibres in the colon, have been shown to
influence the mucosal immunity and provoke the production of interleukin 18 (IL-18) by
enterocytes [52, 53]. Interleukin 18 supports the repair of mucosal tissue by controlling
the production and availability of IL-22 [54], which in turn, prompts epithelial cell prolifer-
ation and antibacterial peptides production. Accordingly, IL-22 induces epithelial repair,
and based on the degree of mucosal damage, it could be pro- or anti-carcinogenic
[54–56]. Furthermore, bacterial SCFAs have been shown to regulate the size and
functions of the regulatory T cell (T-reg) pool. These SCFAs, for example, butyrate,
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have been demonstrated to restrain the inflammation and carcinogenesis of colon by
stimulating the anti-inflammatory cytokine IL-10 production through inducing the T-reg
cells expansion [52, 53, 57]. In this context, B. fragilis, which is a normal component of
the human gut microbiota, has been found to play a role in the differentiation of IL-10-
producing T-reg cells by signalling through its capsular polysaccharide A [58]. Moreover,
B. fragilis was able to protect mice from colitis induced by tri-nitrobenzene sulfonic acid
and infections of Helicobacter hepaticus [58, 59].
3.3.2. Commensal bacteria-inducing carcinogenesis
Dysbiosis (microbiota alterations) or antibiotics treatment has been suggested to modify
the microbiota ability to metabolize oestrogens, which in turn, is thought to be the
non-inflammatory mechanism whereby the microflora adjusts distant malignancies [60].
Furthermore, antibiotics could influence cancer risk through many mechanisms [61].
For instance, it has been found that the use of antibiotics could decrease the ability
of intestinal microbiota to metabolize phytochemicals into compounds that might offer
protection against cancer [62, 63]. However, the correlation between antibiotics use
and cancer risk could be attributed to the effects of antimicrobials on inflammation and
the functions of the immune system [61, 64].
The microbiota has been approved to be direct or indirect inducers of inflammation
development andmaintenance, which has beenwidely accepted to be one of the cancer
hallmarks. Inflammation has been demonstrated to stimulate cancer via increasing
genetic instability. Approximately, 16% of human cancers throughout the world are
caused by infectious agents, especially those associated with chronic inflammation;
with higher percentages in the developing countries than in the developed ones [65].
The microbiota may enhance cancer-promoting conditions, for example, obesity and
metabolic syndromes, and modification of numerous inflammatory and immune mech-
anisms that control the initiation and progression of cancer [66].
The development and progression of cancer at various body sites, such as stomach,
colon, liver, lung, and skin have been linked to microbiome and microbial imbalance
[25, 66]. Dysbiosis disturbs the symbiotic relationship between the resident microbiota
and the host [67]. It has been shown that dysbiosis is able to dysregulate immune and
inflammatory responses of the host against bacteria as well as impairing the control
of pathogenic organisms leading to severe acute and chronic tissue damage [68].
On the other hand, commensal bacteria have been suggested to become pathogenic
when they translocate through the mucosa or under certain conditions, for example,
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immunodeficiency [69]. Eventually, high incidence of certain types of human neoplasms
can occur due to chronic bacterial infections [27]. Hence, tumour development seems to
be a side effect of the bacterial infection [70]. It has been shown that mice undergoing
intestinal dysbiosis lost their ability to produce or respond to IL-18, and the mice were
vulnerable to colon cancer induced by chemicals [30, 71, 72].
Various bacterial genera have been linked with neoplasms, and the infections result-
ing from these bacteria have mutual characteristics [73]. However, the time between the
acquisition of bacterial infection and cancer occurrence is often decades. Carcinogen-
esis appears to result from the long-lasting interactions between the infectious agent,
host’s immune response, and/or host susceptibility [15, 73, 74].
Microbes have been proposed to have an extraordinary pleo-morphological ten-
dency, which might be important for cancer development. Many bacterial spp. have
been verified to play a role as tumour promoters or carcinogens [75]. Some important
bacterial spp. that are capable of causing cancer are presented in the table below.
Convincing evidence have linked gastric cancer andmucosa-associated lymphoid tissue
(MALT) lymphoma with the infections of Helicobacter pylori [76–78]. Hepatobiliary car-
cinoma [79] and gallbladder cancer have been attributed to Salmonella Typhi infections
[15, 80, 81]. Concerning gastrointestinal tract, Campylobacter jejuni has been related
to small intestinal lymphomas [82]. While S. bovis has been linked to colon cancer
(83–85), Citrobacter rodentium has been associated with human colorectal cancer [86].
Fusobacterium nucleatum, which is a Gram-negative anaerobic oral commensal and
periodontal pathogen, has been implicated in colorectal neoplasia [87–88]. Moreover,
Chlamydia pneumoniae as well as Mycobacterium tuberculosis have been correlated
with lung cancer [89–92]. Ocular lymphomas have been attributed to infections with
Chlamydia psittaci [93]. Importantly, E. coli, S. mitis, and Bacillus subtilis together have
been reported to promote tumour cell invasion and angiogenesis along with tumour
metastasis [94]. Altogether, according to what has been mentioned above, preventing
or treating the infection may prevent the cancer from occurrence. However, the vast
majority of individuals infected with cancer-causing bacteria will not develop cancer
[73].
3.4. Bacterial strategies for carcinogenesis
The ability of the inhabitant microorganisms to influence the differentiation, migration,
and functions of myeloid cells can mediate the alterations in the immune response to
infections or neoplasms [96–98]. Carcinogenesis may be induced by bacteria or their
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Table 1: Bacterial spp. associated with certain types of cancer.
Bacteria Cancer References
Campylobacter jejuni Small intestinal lymphoma Mesnard et al. (2012) [82]
Chlamydia pneumoniae Lung cancer Koyi et al. (2001) [89]
Chlamydia psittaci Ocular lymphomas Ferreri et al. (2004) [93]
Citrobacter rodentium Human colorectal cancer Luperchio et al. (2000) [86]
Fusobacterium nucleatum Human colorectal cancer Kostic et al. (2013) [87]
Helicobacter pylori Gastric carcinoma,
Mucosa-associated lymphoid
tissue lymphoma
Correa et al. (1990) [76] Crowe
(2005) [78]
Mycobacterium tuberculosis Lung cancer Gupta et al. (2016) [92]
Porphyromonas gingivalis Pancreatic cancer Jacob (2016) [95]
Salmonella Typhi Hepatobiliary carcinoma,
Gallbladder cancer
Caygill et al. (1995) [79] Dutta
et al. (2000) [80]
Salmonella Typhimurium Hepatobiliary carcinoma Caygill et al. (1995) [79]
Streptococcus bovis Colon cancer Zarkin et al. (1990) [83]
secreting products through many mechanisms, including, immune evasion, immune
suppression, and chronic inflammation [73].
The mechanisms of carcinogenesis have been described well for a number of bac-
terial spp., such as E. coli (enteropathogenic), Enterococcus faecalis, S. gallolyticus, B.
fragilis (enterotoxigenic), and Fusobacterium spp. [87, 99, 100]. Individually, these com-
mensal bacteria could induce carcinogenesis, however, through diverse mechanisms,
for example, quorum sensing and the secretion of antibacterial factors and hormones,
these bacteria may synergistically cause modulation to the composition of microflora-
inducing disease-promoting dysbiosis [100]. Chronic inflammation has been suggested
to be associated with the increased rates of DNA turnover predisposing cells, secondary
to the malignant transformation following the exposure to primary carcinogens [101].
Interestingly, cancer stimulation has been linked to inflammation through the nitrogen
and reactive oxygen species (ROS) produced by the infecting agents. These chemi-
cals have been shown to provoke the occurrence of single-stranded DNA or double-
stranded DNA breaks or DNA cross-links, which subsequently might drive mutations in
tumour suppressor genes or oncogenes, that is, genomic instability [102, 103].
An important role of gut commensal microorganisms in cancer has been revealed
through their modulation of local intestinal carcinogenesis as well as enhancing car-
cinogenesis in distant sterile sites through the alteration of tumour necrosis factor (TNF),
oxidative stress, and leukocyte, or epithelial cell genotoxicity [104, 105]. In addition, the
gut microbiota has been associated with epithelial cell damage, mutation, and genomic
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instability, in part due to inducing the secretion of DNA-damaging ROS and nitrogen
species, and by downregulating the DNA repair genes expression [102].
Strategies that enable bacteria to evade the host’s immune system are also available,
with the toxins being not the only strategy, which will be discussed further. The immune
system can be evaded via biofilm formation, an example is uropathic E. coli, whose
biofilm protects it from the immune system rendering it resistant to antibiotics and
making its infection to be chronic [106]. Furthermore, the oral pathogens, Capno-
cytophaga spp., can inhibit the migration of polymorphonuclear leukocytes; thereby
these species evade phagocytosis [107]. With respect to the immune suppression,
it was documented that strains of Capnocytophaga ochracea, have the capability
to hydrolytically degrading immunoglobulin A (IgA) subclass 1 of the oral cavity. This
characteristic might augment colonization and invasion of oral lesions by many other
bacteria [108].
3.5. Bacterial products that induce malignant transformation
3.5.1. Bacterial toxins
Many bacterial spp. are well-known for producing toxins, some of these products have
been proved to have carcinogenic effects. Bacterial toxins have the ability to kill cells
or at reduced levels are capable of altering cellular processes that control proliferation,
differentiation, and apoptosis. These alterations have been linked with carcinogenesis
and may either inhibit normal cell controls or stimulate cellular abnormalities [109]. Many
bacterial toxins perturb the control of cell growth by disrupting the cellular signals. Due
to their induction of inflammation, toxins are considered prospective tumour promoters
[110]. Cancer development has been attributed to a number of bacterial protein toxins
because of their ability to cause DNA damage [70]. However, DNA damage itself might
not be adequate to raise cancer development. The most harmful type of DNA damage
is double-strand breaks generated by genotoxins, ROS, and ionizing radiation [3].
Interestingly, toxins secreted by various bacteria isolated from normal adjacent breast
cancer tissue are able to induce DNA double-stranded breaks [111]. These bacteria
included several isolates of E. coli and one S. epidermidis that caused DNA damage
due to their ability to produce colibactin, which could cause genomic instability [112], and
later lead to cancer development [113]. Certain pathogenic E. coli strains that colonize
more frequently colon cancers release cytotoxic necrotizing factor (CNF) [114]. This toxin
is an example of cell-cycle stimulators that have been classified as cyclomodulins. The
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toxin has been found to interfere with cell differentiation and promote cellular prolif-
eration [109] by triggering G1-S transition and consequently induces DNA replication
and disrupts the cell cycle of the host. However, the cells do not increase in number,
but they become multinucleated, possibly due to the ability of the toxin to inhibit cell
differentiation and apoptosis [115].
In contrast, other toxins are cell-cycle inhibitors, such as the cycle inhibiting factor (Cif)
and cytolethal distending toxins (CDTs). Both toxins impede mitosis and compromise
the immune system through inhibiting lymphocytes clonal expansion [109]. Concerning
the Cif toxin, it is found in enteropathogenic (EPEC) and enterohaemorrhagic (EHEC) E.
coli [116]. It causes cell arrest at the G2/M phase [117] resulting in host cell modifications
that cause the host cell membrane to attach to the cytoskeleton. This anchoring of
the cytoskeleton blocks mitosis and leads to cellular and nuclear expansion [109, 117].
The CDTs toxin are secreted by several spp. of Gram-negative bacteria, including E.
coli, Campylobacter jejuni, and S. Typhi [116]. The CDT holotoxin is composed of three
different subunits: Cdt A, Cdt B, and Cdt C, which are encoded by three genes located
on the same operon [118]. It has been shown that the CDT and its Cdt B unit are a DNAse
that generates double-stranded DNA breaks resulting in cell cycle arrest, mostly at the
G2 checkpoint [119].
Another toxin is vacuolating cytotoxin A (VacA), encoded by vacA gene in almost
all strains of H. pylori, is greatly correlated with pre-cancerous intestinal metaplasia
and genetic adenocarcinoma [120]. Both VacA and cytotoxin-associated gene-A (CagA)
protein toxins, which are virulence factors of H. pylori, through their expression for a
long time, generate pathologic intestinal hyperplasia in adults [121]. A role for S. Typhi
has been confirmed in colon cancer through its protein toxin Avirulence protein A
(AvrA) [122]. In addition, the increased risk of colon carcinoma has been linked with the
chronic infection with the enterotoxigenic B. fragilis (ETBF) due to its production of a
metalloprotease protein toxin known as B. fragilis toxin (BFT) [123].
3.5.2. Bacterial enzymes
Some enzymes produced by bacteria are potential carcinogens. One such enzyme is
peptidyl arginine deaminases (PAD), which are produced by oral bacteria and associated
with pancreatic cancer [95]. Another enzyme is ß-glucuronidase, which is synthesized
by many bacteria such as the Escherichia/Shigella bacterial group, a member of the
Proteobacteria phylum, as well as Clostridium leptum and Clostridium coccoides, which
belong to the Firmicutes phylum. It has been found that numerous microorganisms
DOI 10.18502/sjms.v14i2.4688 Page 11
Sudan Journal of Medical Sciences Inam Jasim Lafta and Naer Abdulbari Madlood Alkaabawi
correlated with breast cancer share the enzymatic activity of ß-glucuronidase, which
impedes oestrogens conjugation, among other compounds, leaving them as biologically
active hormones [124]. Likewise, a considerable role of ß-glucuronidase has been
demonstrated through its de-conjugation of bisphenol-A, which is one of endocrine
disrupting chemicals, leading to increasing the time of its persistence in an organism.
Some endocrine compounds have been suggested to induce gut microbiota modula-
tions and alter their metabolites, leading to increased inflammation [125].
3.5.3. Other bacterial products
The FadA adhesin/invasin, produced by F. nucleatum, is required for binding and
invasion of normal and cancerous host cells. It is the best characterized virulence factor
whose level has been shown to be elevated in normal tissues adjacent to adenoma and
carcinoma compared to normal individuals without tumour or inflammation [99]. Other
factors that promote tumour cell invasion and angiogenesis include quorum-sensing
peptides such as extracellular death factors (EDF) from E. coli, phosphate regulator G
(PhrG) from Bacillus subtilis, and competence stimulating peptide (CSP) from S. mitis
[94]. These quorum-sensing peptides act through downregulating microRNA-222 and
starting angiogenesis, which stimulates neovascularization leading to tumourmetastasis
[126].
4. Conclusions
From the data reviewed earlier, it can be concluded that commensal microbiota plays
an important role in the prevention of diseases including cancer. The symbiotic relation-
ships between the microbiota and the host confer benefits to the last, in which some
bacteria act as probiotics that sustain host health. Inversely, microbiome alterations (dys-
biosis) have been found to interrupt that symbiotic correlation between the host and the
inhabitant microbiota. Various mechanisms exist by which bacteria and their secreting
products could induce carcinogenesis, including chronic infection, immune evasion, and
immune suppression. Evidence has linked many bacterial infections to carcinogenesis,
such as H. pylori, S. Typhi, C. jejuni, C. psittaci, C. pneumoniae, M. tuberculosis, C.
rodentium, F. nucleatum, and S. bovis. However, the impacts of microflora on cancer
treatment need to be extensively discussed in separate reviews. This tumour-associated
microbiota might have duel effects on cancer therapies, both negatively and positively,
which are not described here.
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5. Recommendations
The authors recommend investigating the correlation between the commensal micro-
biome, antibiotics uptake, and cancer occurrence, especially in Iraq. Another important
issue is evaluating the effects of the microbiome on the currently used anticancer
agents. More attention should be paid for the role that might be played by commensal
bacteria on tumour progression or tumour regression; this can be achieved by doing
more clinical trials in this field, by investigating the possible fungal spp. and yeasts that
might reside tumour tissues, and studying their influences on carcinogenesis along with
cancer therapies.
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